BAXTER INTERNATIONAL INC (BAX) Fundamental Analysis & Valuation

NYSE:BAX • US0718131099

Current stock price

15.97 USD
-0.7 (-4.2%)
At close:
15.921 USD
-0.05 (-0.31%)
After Hours:

This BAX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. BAX Profitability Analysis

1.1 Basic Checks

  • BAX had positive earnings in the past year.
  • BAX had a positive operating cash flow in the past year.
  • In multiple years BAX reported negative net income over the last 5 years.
  • Each year in the past 5 years BAX had a positive operating cash flow.
BAX Yearly Net Income VS EBIT VS OCF VS FCFBAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B -2B 4B

1.2 Ratios

  • The Return On Assets of BAX (-4.77%) is better than 68.25% of its industry peers.
  • The Return On Equity of BAX (-15.61%) is better than 63.49% of its industry peers.
  • BAX has a Return On Invested Capital of 1.97%. This is in the better half of the industry: BAX outperforms 68.78% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for BAX is significantly below the industry average of 9.31%.
Industry RankSector Rank
ROA -4.77%
ROE -15.61%
ROIC 1.97%
ROA(3y)0.7%
ROA(5y)-0.53%
ROE(3y)2.23%
ROE(5y)-4.18%
ROIC(3y)3.01%
ROIC(5y)3.68%
BAX Yearly ROA, ROE, ROICBAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40

1.3 Margins

  • Looking at the Operating Margin, with a value of 3.78%, BAX is in the better half of the industry, outperforming 69.31% of the companies in the same industry.
  • In the last couple of years the Operating Margin of BAX has declined.
  • BAX has a worse Gross Margin (30.68%) than 73.55% of its industry peers.
  • BAX's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 3.78%
PM (TTM) N/A
GM 30.68%
OM growth 3Y-22.24%
OM growth 5Y-24.4%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.08%
GM growth 5Y-5.03%
BAX Yearly Profit, Operating, Gross MarginsBAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. BAX Health Analysis

2.1 Basic Checks

  • BAX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for BAX has been increased compared to 1 year ago.
  • BAX has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for BAX has been reduced compared to a year ago.
BAX Yearly Shares OutstandingBAX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M
BAX Yearly Total Debt VS Total AssetsBAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

2.2 Solvency

  • BAX has an Altman-Z score of 2.17. This is not the best score and indicates that BAX is in the grey zone with still only limited risk for bankruptcy at the moment.
  • BAX has a Altman-Z score of 2.17. This is in the better half of the industry: BAX outperforms 63.49% of its industry peers.
  • The Debt to FCF ratio of BAX is 28.54, which is on the high side as it means it would take BAX, 28.54 years of fcf income to pay off all of its debts.
  • BAX has a better Debt to FCF ratio (28.54) than 69.31% of its industry peers.
  • BAX has a Debt/Equity ratio of 1.55. This is a high value indicating a heavy dependency on external financing.
  • BAX has a worse Debt to Equity ratio (1.55) than 78.84% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.55
Debt/FCF 28.54
Altman-Z 2.17
ROIC/WACC0.25
WACC7.98%
BAX Yearly LT Debt VS Equity VS FCFBAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.3 Liquidity

  • A Current Ratio of 2.31 indicates that BAX has no problem at all paying its short term obligations.
  • BAX has a Current ratio of 2.31. This is comparable to the rest of the industry: BAX outperforms 43.92% of its industry peers.
  • BAX has a Quick Ratio of 1.56. This is a normal value and indicates that BAX is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of BAX (1.56) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.31
Quick Ratio 1.56
BAX Yearly Current Assets VS Current LiabilitesBAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. BAX Growth Analysis

3.1 Past

  • BAX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.24%.
  • Measured over the past years, BAX shows a decrease in Earnings Per Share. The EPS has been decreasing by -5.98% on average per year.
  • BAX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -12.54%.
  • The Revenue has been decreasing by -0.75% on average over the past years.
EPS 1Y (TTM)-16.24%
EPS 3Y-13.44%
EPS 5Y-5.98%
EPS Q2Q%-24.14%
Revenue 1Y (TTM)-12.54%
Revenue growth 3Y-9.39%
Revenue growth 5Y-0.75%
Sales Q2Q%8.03%

3.2 Future

  • Based on estimates for the next years, BAX will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.15% on average per year.
  • Based on estimates for the next years, BAX will show a small growth in Revenue. The Revenue will grow by 2.51% on average per year.
EPS Next Y-14.64%
EPS Next 2Y-4.82%
EPS Next 3Y2.36%
EPS Next 5Y9.15%
Revenue Next Year2.37%
Revenue Next 2Y2.29%
Revenue Next 3Y2.44%
Revenue Next 5Y2.51%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BAX Yearly Revenue VS EstimatesBAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 5B 10B 15B
BAX Yearly EPS VS EstimatesBAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

7

4. BAX Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 7.04, the valuation of BAX can be described as very cheap.
  • Based on the Price/Earnings ratio, BAX is valued cheaply inside the industry as 95.77% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 24.89. BAX is valued rather cheaply when compared to this.
  • Based on the Price/Forward Earnings ratio of 8.24, the valuation of BAX can be described as reasonable.
  • Based on the Price/Forward Earnings ratio, BAX is valued cheaply inside the industry as 96.30% of the companies are valued more expensively.
  • BAX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.19.
Industry RankSector Rank
PE 7.04
Fwd PE 8.24
BAX Price Earnings VS Forward Price EarningsBAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BAX indicates a rather cheap valuation: BAX is cheaper than 87.83% of the companies listed in the same industry.
  • BAX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BAX is cheaper than 80.42% of the companies in the same industry.
Industry RankSector Rank
P/FCF 24.75
EV/EBITDA 11.18
BAX Per share dataBAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.82%
EPS Next 3Y2.36%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

3

5. BAX Dividend Analysis

5.1 Amount

  • With a yearly dividend of 0.24%, BAX is not a good candidate for dividend investing.
  • BAX's Dividend Yield is rather good when compared to the industry average which is at 0.24. BAX pays more dividend than 89.95% of the companies in the same industry.
  • With a Dividend Yield of 0.24, BAX pays less dividend than the S&P500 average, which is at 1.89.
Industry RankSector Rank
Dividend Yield 0.24%

5.2 History

  • The dividend of BAX decreases each year by -6.21%.
  • BAX has paid a dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)-6.21%
Div Incr Years0
Div Non Decr Years0
BAX Yearly Dividends per shareBAX Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6 0.8 1

5.3 Sustainability

  • BAX has negative earnings and hence a negative payout ratio. The dividend may be in danger.
DP-36.36%
EPS Next 2Y-4.82%
EPS Next 3Y2.36%
BAX Yearly Income VS Free CF VS DividendBAX Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B -2B 4B

More info and screens

Find the best dividend stocksShow peers with best dividend

BAX Fundamentals: All Metrics, Ratios and Statistics

BAXTER INTERNATIONAL INC

NYSE:BAX (3/27/2026, 8:04:00 PM)

After market: 15.921 -0.05 (-0.31%)

15.97

-0.7 (-4.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-12
Earnings (Next)04-29
Inst Owners109.5%
Inst Owner Change10.75%
Ins Owners0.28%
Ins Owner Change7.68%
Market Cap8.22B
Revenue(TTM)11.24B
Net Income(TTM)-957.00M
Analysts64.55
Price Target21.95 (37.45%)
Short Float %7.54%
Short Ratio3.75
Dividend
Industry RankSector Rank
Dividend Yield 0.24%
Yearly Dividend0.68
Dividend Growth(5Y)-6.21%
DP-36.36%
Div Incr Years0
Div Non Decr Years0
Ex-Date02-27
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.28%
Min EPS beat(2)-18.72%
Max EPS beat(2)14.16%
EPS beat(4)2
Avg EPS beat(4)0.98%
Min EPS beat(4)-18.72%
Max EPS beat(4)14.16%
EPS beat(8)6
Avg EPS beat(8)3.02%
EPS beat(12)9
Avg EPS beat(12)2.81%
EPS beat(16)10
Avg EPS beat(16)2.49%
Revenue beat(2)1
Avg Revenue beat(2)0.95%
Min Revenue beat(2)-2.38%
Max Revenue beat(2)4.28%
Revenue beat(4)2
Avg Revenue beat(4)0.23%
Min Revenue beat(4)-2.38%
Max Revenue beat(4)4.28%
Revenue beat(8)5
Avg Revenue beat(8)0.31%
Revenue beat(12)7
Avg Revenue beat(12)0.01%
Revenue beat(16)7
Avg Revenue beat(16)-1.2%
PT rev (1m)-1.17%
PT rev (3m)-10.58%
EPS NQ rev (1m)0.69%
EPS NQ rev (3m)-34.91%
EPS NY rev (1m)-14.62%
EPS NY rev (3m)-15%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.68%
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)0.39%
Valuation
Industry RankSector Rank
PE 7.04
Fwd PE 8.24
P/S 0.73
P/FCF 24.75
P/OCF 9.72
P/B 1.34
P/tB N/A
EV/EBITDA 11.18
EPS(TTM)2.27
EY14.21%
EPS(NY)1.94
Fwd EY12.13%
FCF(TTM)0.65
FCFY4.04%
OCF(TTM)1.64
OCFY10.28%
SpS21.85
BVpS11.91
TBVpS-6.16
PEG (NY)N/A
PEG (5Y)N/A
Graham Number24.67
Profitability
Industry RankSector Rank
ROA -4.77%
ROE -15.61%
ROCE 2.49%
ROIC 1.97%
ROICexc 2.22%
ROICexgc 5.77%
OM 3.78%
PM (TTM) N/A
GM 30.68%
FCFM 2.95%
ROA(3y)0.7%
ROA(5y)-0.53%
ROE(3y)2.23%
ROE(5y)-4.18%
ROIC(3y)3.01%
ROIC(5y)3.68%
ROICexc(3y)3.41%
ROICexc(5y)4.11%
ROICexgc(3y)9.09%
ROICexgc(5y)11.24%
ROCE(3y)3.97%
ROCE(5y)4.78%
ROICexgc growth 3Y-20.11%
ROICexgc growth 5Y-19.9%
ROICexc growth 3Y-20.01%
ROICexc growth 5Y-27.24%
OM growth 3Y-22.24%
OM growth 5Y-24.4%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.08%
GM growth 5Y-5.03%
F-Score4
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 1.55
Debt/FCF 28.54
Debt/EBITDA 6.74
Cap/Depr 52.29%
Cap/Sales 4.56%
Interest Coverage 1.4
Cash Conversion 60.1%
Profit Quality N/A
Current Ratio 2.31
Quick Ratio 1.56
Altman-Z 2.17
F-Score4
WACC7.98%
ROIC/WACC0.25
Cap/Depr(3y)50.61%
Cap/Depr(5y)56.74%
Cap/Sales(3y)5.15%
Cap/Sales(5y)5.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.24%
EPS 3Y-13.44%
EPS 5Y-5.98%
EPS Q2Q%-24.14%
EPS Next Y-14.64%
EPS Next 2Y-4.82%
EPS Next 3Y2.36%
EPS Next 5Y9.15%
Revenue 1Y (TTM)-12.54%
Revenue growth 3Y-9.39%
Revenue growth 5Y-0.75%
Sales Q2Q%8.03%
Revenue Next Year2.37%
Revenue Next 2Y2.29%
Revenue Next 3Y2.44%
Revenue Next 5Y2.51%
EBIT growth 1Y-55.07%
EBIT growth 3Y-29.54%
EBIT growth 5Y-24.96%
EBIT Next Year38.22%
EBIT Next 3Y13.43%
EBIT Next 5Y17.39%
FCF growth 1Y-42.06%
FCF growth 3Y-14.54%
FCF growth 5Y-22.12%
OCF growth 1Y-17.08%
OCF growth 3Y-11.3%
OCF growth 5Y-14.67%

BAXTER INTERNATIONAL INC / BAX Fundamental Analysis FAQ

What is the fundamental rating for BAX stock?

ChartMill assigns a fundamental rating of 4 / 10 to BAX.


Can you provide the valuation status for BAXTER INTERNATIONAL INC?

ChartMill assigns a valuation rating of 7 / 10 to BAXTER INTERNATIONAL INC (BAX). This can be considered as Undervalued.


What is the profitability of BAX stock?

BAXTER INTERNATIONAL INC (BAX) has a profitability rating of 4 / 10.


Can you provide the expected EPS growth for BAX stock?

The Earnings per Share (EPS) of BAXTER INTERNATIONAL INC (BAX) is expected to decline by -14.64% in the next year.


How sustainable is the dividend of BAXTER INTERNATIONAL INC (BAX) stock?

The dividend rating of BAXTER INTERNATIONAL INC (BAX) is 3 / 10 and the dividend payout ratio is -36.36%.